Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer.
chemotherapy
haemostatic biomarker
lung cancer
prognostic model
systemic inflammation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Jun 2020
18 Jun 2020
Historique:
received:
26
05
2020
revised:
12
06
2020
accepted:
16
06
2020
entrez:
24
6
2020
pubmed:
24
6
2020
medline:
24
6
2020
Statut:
epublish
Résumé
Systemic inflammation and activation of haemostasis are common in patients with lung cancer. Both conditions support tumour growth and metastasis. Therefore, inflammatory and haemostatic biomarkers might be useful for prediction of survival and therapy response. Patients with unresectable/metastatic lung cancer initiating 1st-line chemotherapy (
Identifiants
pubmed: 32570944
pii: cancers12061619
doi: 10.3390/cancers12061619
pmc: PMC7352812
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Oesterreichische Nationalbank
ID : 17828
Organisme : Austrian Science Fund
ID : Special Research Program SFB F5405-B21
Références
Medicine (Baltimore). 2019 Jun;98(26):e16238
pubmed: 31261584
Br J Cancer. 2011 Feb 15;104(4):726-34
pubmed: 21266974
Arch Med Sci. 2019 Sep;15(5):1147-1153
pubmed: 31572459
Sci Rep. 2016 Oct 05;6:34823
pubmed: 27703265
J Clin Oncol. 2011 May 20;29(15):2099-103
pubmed: 21464402
Int J Environ Res Public Health. 2013 Aug 27;10(9):3886-907
pubmed: 23985773
Ann Oncol. 2019 May;30(5):863-870
pubmed: 31987360
Cancer. 2001 Nov 1;92(9):2399-405
pubmed: 11745296
J Thorac Oncol. 2010 Dec;5(12):2024-36
pubmed: 21155185
Oncol Rep. 2008 Jul;20(1):123-8
pubmed: 18575726
Biom J. 2018 May;60(3):431-449
pubmed: 29292533
J Clin Oncol. 2009 Sep 1;27(25):4124-9
pubmed: 19636003
Cancer. 2003 Jun 15;97(12):3044-52
pubmed: 12784340
Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2176-81
pubmed: 19778945
Eur J Cancer. 1997 Jan;33(1):50-5
pubmed: 9071899
Heart. 2012 May;98(9):683-90
pubmed: 22397945
Br J Cancer. 2017 Aug 22;117(5):744-751
pubmed: 28728168
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Exp Ther Med. 2013 May;5(5):1351-1354
pubmed: 23737877
Br J Cancer. 2003 Sep 15;89(6):1028-30
pubmed: 12966420
Oncotarget. 2017 Aug 28;8(66):110606-110613
pubmed: 29299172
Respir Med. 2013 Mar;107(3):451-7
pubmed: 23200643
JAMA. 1982 May 14;247(18):2543-6
pubmed: 7069920
BMC Cancer. 2018 Dec 10;18(1):1235
pubmed: 30526532
Haematologica. 2012 Aug;97(8):1158-64
pubmed: 22371182
Thromb Haemost. 1994 Jun;71(6):719-22
pubmed: 7974338
Asian Pac J Cancer Prev. ;18(5):1417-1421
pubmed: 28612596
Blood. 2008 Oct 1;112(7):2703-8
pubmed: 18539899
Best Pract Res Clin Haematol. 2009 Mar;22(1):49-60
pubmed: 19285272
Oncol Res Treat. 2019;42(10):523-531
pubmed: 31319409
J Cancer. 2018 Oct 10;9(21):3904-3911
pubmed: 30410594
Clin Transl Oncol. 2012 Nov;14(11):864-9
pubmed: 22855161
Br J Cancer. 1999 Feb;79(3-4):472-7
pubmed: 10027315
Cancer Res. 2002 Dec 1;62(23):6966-72
pubmed: 12460914
Clin Chem. 2009 Oct;55(10):1834-42
pubmed: 19661141
Ann Oncol. 2013 Oct;24 Suppl 6:vi99-105
pubmed: 23813929
Thromb Haemost. 2011 Nov;106(5):908-13
pubmed: 21901234
PLoS One. 2017 Sep 8;12(9):e0184412
pubmed: 28886134
Lifetime Data Anal. 1996;2(4):315-28
pubmed: 9384628
J Clin Oncol. 2010 Jun 1;28(16):2719-26
pubmed: 20421535
J Thorac Oncol. 2010 Jan;5(1):29-33
pubmed: 19952801
Hematol Oncol Clin North Am. 2014 Aug;28(4):671-81, vi
pubmed: 25064707
Pulmonology. 2019 May - Jun;25(3):181-183
pubmed: 30935945
J Clin Epidemiol. 2001 Apr;54(4):343-9
pubmed: 11297884
Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1221-1227
pubmed: 31015200
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593